Patents Represented by Attorney Myrexis IP Group

Find this attorney in the Justia Lawyer Directory

Therapeutic compounds and uses thereof

Patent number: 8017780

Abstract: The invention provides novel therapeutic compounds, pharmaceutical compositions comprising these compounds, and methods for using these compounds and compositions to treat diseases and disorders such as cancer.

Type: Grant

Filed: October 9, 2009

Date of Patent: September 13, 2011

Assignee: Myrexis, Inc.

Inventors: Ashok Bajji, Se-Ho Kim, Rajendra Tangallapally
4-arylamin-or-4-heteroarylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof

Patent number: 7989462

Abstract: Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

Type: Grant

Filed: July 3, 2007

Date of Patent: August 2, 2011

Assignee: Myrexis, Inc.

Inventors: Sui Xiong Cai, Mark B. Anderson, Adam Willardsen, Nilantha Sudath Sirisoma, Hong Zhang, Kazuyuki Suzuki
Immunizing compositions comprising HIV-1 proviral constructs with an inactive p6 gag TSG101 UEV binding domain capable of producing budding-defective viral particles that remain tethered to the cell surface

Patent number: 7943146

Abstract: The present invention provides methods for preventing and treating HIV infection and AIDS by introducing cells displaying HIV late-domain phenotype into a patient, or by administering to a patient nucleic acids, polypeptides or small organic compounds to cause the formation of cells displaying HIV late-domain phenotype in the body of the patient.

Type: Grant

Filed: December 20, 2002

Date of Patent: May 17, 2011

Assignee: Myrexis, Inc.

Inventors: Adrian Hobden, Kenton Zavitz, Scott Morham

Therapeutic compounds and uses thereof

4-arylamin-or-4-heteroarylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof

Immunizing compositions comprising HIV-1 proviral constructs with an inactive p6 gag TSG101 UEV binding domain capable of producing budding-defective viral particles that remain tethered to the cell surface